CfA Seminar: Targeting the cough reflex for new treatments of airway disease
Welcome to the CfA seminar 16th March by Maria Belvisi, Professor of Respiratory Pharmacology, the National Heart and Lung Institute, Imperial College, London, UK
Title: Targeting the cough reflex for new treatments of airway disease
About Professor Maria Belvisi
Professor Belvisi is an internationally recognized expert in the respiratory field with both academic and industrial experience.
Her research is focused on the cellular and molecular mechanisms of asthma, COPD and chronic cough, and developing therapies for these diseases. Her research is translational and takes data generated in vitro through to in vivo models and clinical studies with collaborators.
Together with Peter Barnes at NHLI she was involved in generating key data sets during the developement of tiotropium bromide (Spiriva) a long acting muscarinig receptor antagonist used as a bronchodilator for the treatment of chronic obstructive pulmonary disease.
In 2010 she formed, together with Dr Mark Birrell, IR Pharma a preclinical respiratory drug discovery organisation which is part of the Imperial Innovations portfolio of companies.